当前位置： SCI文献检索 > CLINICAL DRUG INVESTIGATION期刊下所有文献 > Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children.

Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children.

Abstract：

:Since the introduction of the first gadolinium-based contrast agent (GBCA) approximately 25 years ago, magnetic resonance imaging (MRI) using GBCAs has revolutionized diagnostic and follow-up imaging of pathological lesions, with clinical applications expanded to encompass almost all fields of medicine. Intravenous gadobutrol (Gadovist™ [EU]; Gadavist(®) [USA]) is a second-generation extracellular non-ionic macrocyclic GBCA that is used in patients undergoing diagnostic contrast-enhanced MRI for visualization of pathological lesions in the CNS and all other body regions or for contrast-enhanced magnetic resonance angiography (MRA) to evaluate perfusion and flow-related abnormalities. Its unique physicochemical profile, along with the high thermostability of macrocyclic GBCAs, means gadobutrol is formulated at twice the gadolinium ion concentration of other currently licensed GBCAs. This reduces the injection volume and provides a narrower bolus, thereby improving image enhancement. Based on extensive clinical experience in a broad range of patients, including paediatric and adult patients (younger and elderly adults), and those with moderate to severe hepatic or renal impairment or cardiovascular disorders, gadobutrol is an effective and generally well tolerated extracellular GBCA for patients undergoing diagnostic contrast-enhanced MRI and contrast-enhanced MRA. As with all macrocyclic GBCAs, the potential for gadobutrol to cause nephrogenic systemic fibrosis appears to be lower than with linear GBCAs.

journal_name

Clin Drug Investig

journal_title

Clinical drug investigation

authors

Scott LJ

doi

10.1007/s40261-013-0066-0

subject

Has Abstract

pub_date

2013-04-01 00:00:00

pages

303-14

issue

4

eissn

1173-2563

issn

1179-1918

journal_volume

33

pub_type

杂志文章,评审

相关文献

CLINICAL DRUG INVESTIGATION文献大全

Weekly oral alendronic Acid in male osteoporosis.
abstract：OBJECTIVE:To evaluate the efficacy and tolerability of alendronic acid 70mg once weekly for the treatment of male osteoporosis. PATIENTS AND METHODS:This randomised, double-blind, placebo-controlled, 12-month trial compared the effect of alendronic acid 70mg once weekly or placebo (randomised 2 : 1) on bone mineral de...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.2165/00044011-200424060-00003

authors： Miller PD,Schnitzer T,Emkey R,Orwoll E,Rosen C,Ettinger M,Vandormael K,Daifotis A

更新日期：2004-01-01 00:00:00
Intraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations : a retrospective, multicentre, cross-sectional study.
abstract：OBJECTIVE:The aim of this study was to confirm randomized clinical trial results showing that a fixed timolol/travoprost combination (TT; DuoTrav) controls intraocular pressure (IOP) better than a fixed timolol/latanoprost combination (TL; Xalacom) in everyday ophthalmic practice, when measured in the morning and >24 h...

journal_title：Clinical drug investigation

pub_type： 杂志文章,多中心研究,随机对照试验

doi：10.2165/0044011-200828120-00004

authors： Denis P,Lafuma A,Jeanbat V,Laurendeau C,Berdeaux G

更新日期：2008-01-01 00:00:00
Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.
abstract：BACKGROUND:Overactive bladder is a prevalent condition worldwide that is associated with a considerable burden, both on the patient and on society. OBJECTIVE:Our objective was to assess the economic value of fesoterodine compared with tolterodine extended release (ER) for the treatment of overactive bladder (OAB) with...

journal_title：Clinical drug investigation

pub_type： 杂志文章,评审

doi：10.1007/s40261-014-0178-1

authors： Angulo JC,Valpas A,Rejas J,Linden K,Kvasz M,Snedecor SJ

更新日期：2014-05-01 00:00:00
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.
abstract：BACKGROUND:Rates and impacts of worsening symptoms in patients with psoriasis have not been well characterized. OBJECTIVES:To assess the risk of clinically relevant worsening of psoriasis symptoms in patients treated with adalimumab versus placebo and to determine the health-related quality-of-life (HRQOL) impacts of ...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.2165/11539360-000000000-00000

authors： Papp KA,Signorovitch J,Ramakrishnan K,Yu AP,Gupta SR,Bao Y,Mulani PM

更新日期：2011-01-01 00:00:00
Topical application of dexamethasone to prevent cerebral vasospasm after aneurysmal subarachnoid haemorrhage: a pilot study.
abstract：BACKGROUND AND OBJECTIVE:Cerebral vasospasm is a common and serious complication of aneurysmal subarachnoid haemorrhage (SAH). Many studies have revealed a role of inflammation in the development of cerebral vasospasm. This study aimed to investigate whether topically administered dexamethasone could attenuate vasospas...

journal_title：Clinical drug investigation

pub_type： 临床试验,杂志文章

doi：10.2165/00044011-200727120-00004

authors： Fei L,Golwa F

更新日期：2007-01-01 00:00:00
Immediate neurological recovery following perispinal etanercept years after brain injury.
abstract：:Positron emission tomographic brain imaging and pathological examination have revealed that a chronic, intracerebral neuroinflammatory response lasting for years after a single brain injury may occur in humans. Evidence suggests the immune signaling molecule, tumor necrosis factor (TNF), is centrally involved in this ...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.1007/s40261-014-0186-1

authors： Tobinick E,Rodriguez-Romanacce H,Levine A,Ignatowski TA,Spengler RN

更新日期：2014-05-01 00:00:00
Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.
abstract：BACKGROUND AND OBJECTIVE:Several systematic reviews and meta-analyses have been conducted including an analysis to investigate the difference between ethnic groups in the glucose-lowering efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors. This study assessed the factors related to the glucose-lowering efficacy and ...

journal_title：Clinical drug investigation

pub_type： 杂志文章,meta分析,评审

doi：10.1007/s40261-016-0478-8

authors： Fujita K,Kaneko M,Narukawa M

更新日期：2017-03-01 00:00:00
US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.
abstract：:Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12 weeks after the end of treatment (SVR12) across five clinical trials in subjects infected with chronic hepatitis C virus (HCV) genotype 1, including those with advanced chronic kidney disease (CKD), and GT4. Despite favorable results overall,...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.1007/s40261-017-0492-5

authors： Boyd SD,Tracy L,Komatsu TE,Harrington PR,Viswanathan P,Murray J,Sherwat A

更新日期：2017-04-01 00:00:00
Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study.
abstract：BACKGROUND AND OBJECTIVES:Hypertension, one of the major treatable cardiovascular (CV) risk factors, usually occurs in association with other major risk factors. As well as providing rapid blood pressure (BP) goal attainment, antihypertensive therapy should also provide reductions in CV events and mortality in a wide r...

journal_title：Clinical drug investigation

pub_type： 临床试验,杂志文章,多中心研究

doi：10.2165/00044011-200828110-00001

authors： Ogilvie RI,Anand S,Roy P,De Souza S,PEACH investigators.

更新日期：2008-01-01 00:00:00
Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
abstract：BACKGROUND AND OBJECTIVES:The new oral anticoagulants (NOACs) are used for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillation (AF) and those at risk of deep venous thrombosis. Their rapid onset of action and predictable pharmacokinetic and pharmacodynamic profiles make them...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.1007/s40261-016-0436-5

authors： Acanfora D,Acanfora C,Scicchitano P,Longobardi M,Furgi G,Casucci G,Lanzillo B,Dentamaro I,Zito A,Incalzi RA,Ciccone MM

更新日期：2016-10-01 00:00:00
Safety of lornoxicam in the treatment of postoperative pain: a post-marketing study of analgesic regimens containing lornoxicam compared with standard analgesic treatment in 3752 day-case surgery patients.
abstract：BACKGROUND:Post-marketing surveillance studies can provide supplemental data on the safety of medications in the general population. OBJECTIVE:This study aimed to evaluate the safety of analgesic regimens including the NSAID lornoxicam in the short-term treatment of postoperative pain in a clinically relevant populati...

journal_title：Clinical drug investigation

pub_type： 杂志文章,多中心研究,随机对照试验

doi：10.2165/11538860-000000000-00000

authors： Rawal N,Krøner K,Simin-Geertsen M,Hejl C,Likar R

更新日期：2010-01-01 00:00:00
First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects.
abstract：BACKGROUND AND OBJECTIVES:Matrix metalloproteinases (MMPs) are proteases with different biological and pathological activities, and many have been linked to several diseases. Targeting individual MMPs may offer a safer therapeutic potential for several diseases. We assessed the safety, tolerability, and pharmacokinetic...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.1007/s40261-020-00981-9

authors： Abd-Elaziz K,Voors-Pette C,Wang KL,Pan S,Lee Y,Mao J,Li Y,Chien B,Lau D,Diamant Z

更新日期：2021-01-01 00:00:00
Regression and Genomic Analyses on the Association Between Dose-Normalized Mycophenolic Acid Exposure and Absolute Neutrophil Count in Steroid-Free, De Novo Kidney Transplant Recipients.
abstract：BACKGROUND AND OBJECTIVES:The hematological side effects associated with mycophenolic acid (MPA) are relatively common and have severe consequences. The majority of literature data have not shown clear consistency in the MPA exposure-neutropenia relationship. We hypothesized that (i) adult de novo kidney transplant rec...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.1007/s40261-018-0694-5

authors： Kiang TKL,Partovi N,Shapiro RJ,Berman JM,Collier AC,Ensom MHH

更新日期：2018-11-01 00:00:00
Prescription Drug Price Paradox: Cost Analysis of Canadian Online Pharmacies versus US Medicare Beneficiaries for the Top 100 Drugs.
abstract：BACKGROUND AND OBJECTIVES:Despite the introduction of Medicare Part D (MPD) and 2012 Affordable Care Act (ACA), patients have a cost burden due to increases in drug prices. To overcome cost barriers, some patients purchase their medications from Canadian online pharmacies as Canadian prescription drug prices are believ...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.1007/s40261-017-0556-6

authors： Kim SH,Ryu YJ,Cho NE,Kim AE,Chang J

更新日期：2017-10-01 00:00:00
Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
abstract：:Early initiation of rational and effective combination therapy consisting of antihypertensive drugs with two different and complementary mechanisms of actions is increasingly becoming accepted in clinical practice and by guidelines as a first-line approach to control blood pressure (BP) and prevent cardiovascular outc...

journal_title：Clinical drug investigation

pub_type： 杂志文章,评审

doi：10.2165/11538440-000000000-00000

authors： da Silva PM

更新日期：2010-01-01 00:00:00
Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.
abstract：OBJECTIVE:To compare changes in lipid levels (total cholesterol [total-C], low-density lipoprotein cholesterol [LDL-C], triglycerides [TG], and high-density lipoprotein cholesterol [HDL-C]) for patients who switched from standard fenofibrate 160 mg (requiring dosing with food) to fenofibrate 145 mg with no food effect ...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.2165/00044011-200828100-00002

authors： Davidson MH,Jones PH

更新日期：2008-01-01 00:00:00
Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.
abstract：:The aim of this case study was to examine the efficacy of a dipeptidyl peptidase-4 inhibitor (anagliptin) and an α-glucosidase inhibitor (miglitol) when added to ongoing insulin treatment in patients with type 2 diabetes mellitus. Continuous glucose monitoring was performed in four Japanese insulin-treated inpatients ...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.1007/s40261-014-0260-8

authors： Kishimoto M,Noda M

更新日期：2015-02-01 00:00:00
Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
abstract：BACKGROUND AND OBJECTIVE:Gemigliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus. This study evaluated possible pharmacodynamic and pharmacokinetic interactions between gemigliptin and metformin and investigated their tolerability. METHODS:A randomized, open-la...

journal_title：Clinical drug investigation

pub_type： 杂志文章,随机对照试验

doi：10.1007/s40261-014-0184-3

authors： Shin D,Cho YM,Lee S,Lim KS,Kim JA,Ahn JY,Cho JY,Lee H,Jang IJ,Yu KS

更新日期：2014-06-01 00:00:00
Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects.
abstract：BACKGROUND AND OBJECTIVE:Following oral administration of abiraterone acetate, the parent compound abiraterone acetate is rapidly metabolized to abiraterone. To our knowledge, bioanalytical methods to date have not been able to detect the parent compound in human plasma, and bioassay was only performed on the metabolit...

journal_title：Clinical drug investigation

pub_type： 临床试验,杂志文章

doi：10.1007/s40261-019-00752-1

authors： Bouhajib M,Tayab Z

更新日期：2019-03-01 00:00:00
Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.
abstract：BACKGROUND AND OBJECTIVE:Injectable collagenase Clostridium histolyticum is efficacious in correcting Dupuytren's contracture as assessed by changes in the angle of contracture and range of motion (ROM). However, clinically important changes in ROM have not been evaluated in depth. The objective of this secondary analy...

journal_title：Clinical drug investigation

pub_type： 杂志文章,随机对照试验

doi：10.1007/BF03256918

authors： Witthaut J,Bushmakin AG,Gerber RA,Cappelleri JC,Le Graverand-Gastineau MP

更新日期：2011-11-01 00:00:00
Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension.
abstract：BACKGROUND:Dutasteride is a dual inhibitor of type I and type II 5α-reductases and provides nearly complete suppression of dihydrotestosterone, which plays a key role in the aetiology and development of benign prostatic hyperplasia (BPH). Most knowledge about the efficacy and safety of dutasteride in BPH derives from t...

journal_title：Clinical drug investigation

pub_type： 杂志文章,多中心研究,随机对照试验

doi：10.2165/11593750-000000000-00000

authors： Na Y,Ye Z,Zhang S,Chinese Dutasteride Phase III Trial (ARIA108898) Study Group.

更新日期：2012-01-01 00:00:00
Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain.
abstract：BACKGROUND AND OBJECTIVES:Oxycodone tamper resistant (OTR) is a new extended-release abuse-deterrent formulation providing improvements in the tamper resistant characteristics. This study aimed to investigate the pharmacokinetic properties of the new OTR tablets and evaluate the bioequivalence of oxycodone from OTR and...

journal_title：Clinical drug investigation

pub_type： 杂志文章,随机对照试验

doi：10.1007/s40261-019-00870-w

authors： Luo Z,Miao J,Shu S,Wang Y,Zhu X,Hu C,Shen Y

更新日期：2020-02-01 00:00:00
Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
abstract：BACKGROUND AND OBJECTIVES:Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor under clinical investigation in solid tumours. This study evaluated the influence of P-glycoprotein (P-gp) inhibition (single-dose rifampicin) and simultaneous cytochrome P450 3A4 (CYP3A4)/P-gp induction (multiple-dose rifampicin) ...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.1007/s40261-014-0217-y

authors： Shumaker RC,Aluri J,Fan J,Martinez G,Thompson GA,Ren M

更新日期：2014-09-01 00:00:00
Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
abstract：BACKGROUND AND OBJECTIVES:The time-course when changes in glycemic control and body weight were first manifest in patients with type 2 diabetes mellitus (T2DM) treated with a combination of insulin degludec and liraglutide (IDegLira) was assessed, comparing IDegLira to its individual components. METHODS:Data from week...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.1007/s40261-016-0376-0

authors： Vilsbøll T,Vora J,Jarlov H,Kvist K,Blonde L

更新日期：2016-04-01 00:00:00
Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group st
abstract：BACKGROUND AND OBJECTIVE:Inhaled corticosteroid (ICS)/long-acting beta(2)-agonist (LABA) combinations are the preferred maintenance therapy for adult asthma patients uncontrolled by ICS alone. Supporting data are largely from mixed populations of adolescents and adults, although ICS/LABA combinations are not approved f...

journal_title：Clinical drug investigation

pub_type： 杂志文章,随机对照试验

doi：10.2165/11533420-000000000-00000

authors： Aalbers R

更新日期：2010-01-01 00:00:00
Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.
abstract：BACKGROUND AND OBJECTIVES:Cancer pain affects patients at all stages of the disease and there are clear guidelines for its management. Morphine is considered the first-choice strong opioid in the treatment of moderate-to-severe pain; however, numerous studies have shown that oxycodone controlled-release (CR) has a simi...

journal_title：Clinical drug investigation

pub_type： 临床试验,杂志文章,多中心研究

doi：10.2165/00044011-200828070-00001

authors： Silvestri B,Bandieri E,Del Prete S,Ianniello GP,Micheletto G,Dambrosio M,Sabbatini G,Endrizzi L,Marra A,Aitini E,Calorio A,Garetto F,Nastasi G,Piantedosi F,Sidoti V,Spanu P

更新日期：2008-01-01 00:00:00
Efficacy and tolerability of a fixed-dose combination of metoprolol extended release/amlodipine in patients with mild-to-moderate hypertension: a randomized, parallel-group, multicentre comparison with losartan plus amlodipine.
abstract：BACKGROUND:Epidemiological studies and clinical trials have shown that prevention of cardiovascular disease, the ultimate goal of hypertension treatment, requires a sufficient reduction in blood pressure. OBJECTIVE:The primary objective of this study was to compare the mean decrease in systolic (SBP) and diastolic (DB...

journal_title：Clinical drug investigation

pub_type： 杂志文章,多中心研究,随机对照试验

doi：10.2165/11531770-000000000-00000

authors： Pareek A,Chandurkar NB,Sharma R,Tiwari D,Gupta BS

更新日期：2010-01-01 00:00:00
Facial Paralysis Following Influenza Vaccination: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System Database.
abstract：BACKGROUND AND OBJECTIVE:Several cases of facial paralysis have been reported following influenza vaccination; however, recent surveillance studies have not shown an increased risk. In this study, we analyzed the vaccine adverse event reporting system (VAERS) data to determine whether the facial paralysis reporting rat...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.1007/s40261-020-00952-0

authors： Kamath A,Maity N,Nayak MA

更新日期：2020-09-01 00:00:00
Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia.
abstract：BACKGROUND AND OBJECTIVES:First-line treatment of chronic phase (CP) chronic myeloid leukemia (CML) is based on the first-generation tyrosine kinase inhibitor (TKI) imatinib or the second-generation TKIs dasatinib or nilotinib. Thanks to the efficacy of TKIs, CML has switched from a fatal to a 'chronic' pathology, and ...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.1007/s40261-018-0676-7

authors： Bettiol A,Marconi E,Lombardi N,Crescioli G,Gherlinzoni F,Walley T,Vannacci A,Chinellato A,Giusti P

更新日期：2018-09-01 00:00:00
Treatment of Aphthous Stomatitis with topical Alchemilla vulgaris in glycerine.
abstract：BACKGROUND AND OBJECTIVE:Recurrent aphthous ulceration is the most common oral mucosal disease known. It presents as three types: minor (most prevalent), major and herpetiform. However, there are no well established effective and reliable treatments of this condition. Alchemilla vulgaris (Lady's Mantle) has traditional...

journal_title：Clinical drug investigation

pub_type： 杂志文章

doi：10.2165/00044011-200626100-00003

authors： Shrivastava R,John GW

更新日期：2006-01-01 00:00:00